Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

BACKGROUND: The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer. However, duration of response is often limited and there is currently no reliable predi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ioannou, N, Dalgleish, A G, Seddon, A M, Mackintosh, D, Guertler, U, Solca, F, Modjtahedi, H
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2011
Sujets:
Translational Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3242519/
https://ncbi.nlm.nih.gov/pubmed/21970876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.396
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires